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Abstract
Objectives—This study aims to evaluate the effect of co-trimoxazole (CTX) prophylaxis on 
mortality reduction among HIV-infected patients receiving antiretroviral therapy (ART) in Henan 
Province, China.
Design—We conducted a retrospective study.
Methods—All individuals aged 15 years and older who initiated ART between 2008 and 2010 in 
Henan Province with completed CTX prophylaxis treatment information were included. The effect 
of CTX prophylaxis was estimated using Kaplan-Meier survival analysis and multivariate Cox 
proportional hazard modeling for mortality at 3-months and 12-months after ART initiation.
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Results—Overall mortality among patients receiving both ART and CTX was nearly double at 
3-months after ART initiation compared with that at 12-months (12.4 per 100 PY vs 6.3 per 100 
PY, p<0.01). After adjusting for gender, age, TB history, year of ART initiation and CD4 count at 
ART initiation, CTX was associated with a significant reduction in 12-month mortality (adjusted 
hazard ratio (AHR) = 0.65, 95% confidence interval (CI): 0.44 – 0.95; p = 0.027) compared with 
persons not receiving CTX. The protective effect was more pronounced in the first 3 months after 
ART initiation (AHR = 0.53, 95% CI: 0.32 – 0.89; p = 0.017).
Conclusion—CTX prophylaxis together with ART reduced mortality of adult HIV patients 
during the first 12 months of ART in Henan Province, China. The effect was highest in the first 3 
months of ART. CTX should be prescribed to all HIV-infected adults who initiate ART.
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INTRODUCTION
By 2011, an estimated 780,000 people were living with human immunodeficiency virus 
(HIV) in China [1]. To respond to the HIV epidemic, the Chinese government started the 
National Free Antiretroviral Treatment Program (NFATP) in 2003 to provide free 
antiretroviral therapy (ART) to all eligible patients [2–5]. Overall HIV-associated mortality 
rate decreased from 39.3% in 2002 to 14.2% in 2009 due to the increasing coverage of 
NFATP [6]. Yet a substantial number of deaths still occur each year among people living 
with HIV/acquired immunodeficiency syndrome (AIDS), especially those not on ART and 
those with only a short treatment history [7]. HIV infection remains the leading cause of 
death among all notifiable infectious diseases in China [8]. Therefore, it is of great 
importance to explore additional interventions to further reduce HIV-related deaths.
Co-trimoxazole (CTX) prophylaxis has been associated with a reduction in mortality and 
morbidity among HIV-infected people both not on ART [9–15] and on ART [16–18]. A 
meta-analysis of nine articles found CTX prophylaxis reduced mortality by 58% among 
HIV-infected individuals older than 13 years who were receiving ART [16]. Furthermore, 
two studies in Africa showed CTX prophylaxis had the most significant effect during the 
first 3–6 months after ART initiation [17, 18]. In addition, from an economic perspective, 
CTX prophylaxis is cost-effective in averting mortality among patients on ART [19–22].
In 2005, the Chinese Ministry of Health issued national guidelines on CTX prophylaxis for 
preventing HIV-related opportunistic infections (OIs) [23]. There has been insufficient data 
in China to illustrate the actual coverage of CTX prophylaxis among people living with 
HIV/AIDS. However, a five-year national observational cohort study showed that less than a 
third (26.2%) of 69,943 HIV-infected individuals who were on ART in China received CTX 
either for prophylaxis or treatment of opportunistic infections during 2002 to 2009 [6]; these 
data suggest that implementation of the guidelines has been suboptimal. The aim of this 
study was to investigate the effect of CTX prophylaxis on survival among HIV-infected 
adults on ART by utilizing the data from the Henan Provincial Free Antiretroviral Treatment 
Program database.
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The NFATP in China has been previously described [3–5, 7]. In summary, after a pilot in 
2002, the NFATP was scaled up in 2003 among former plasma donors. An electronic 
database was established in late 2004 [5] to collect information on all ART eligible patients 
across China through standardized case report forms (CRFs) [5]. The CRFs collect 
demographic information, laboratory testing results, clinical signs and symptoms at 
treatment initiation and at follow-up visits. Regimen change and treatment outcome (lost to 
follow-up, treatment termination and death) are also collected using CRFs during follow-up 
visits [3]. Self-report of missing any dose of ART during the last 7 days was used as a proxy 
for non-adherence to ART and CTX prophylaxis. The China Free Antiretroviral Therapy 
Manual was also developed in 2004 to serve as the national technical guideline of NFATP 
[4].
Henan Province, located in central China, has the largest HIV cohort caused by unsafe 
commercial plasma donation in the world [24–26]. It was the site of the first pilot of NFATP 
[4]. The ART program database of Henan Province, part of the NFATP database, was 
established in July 2006 [7] and covers all patients receiving free ART in the province. The 
Henan Provincial free ART program database contains almost half of patients in the NFATP 
database [5]. CTX prophylaxis eligibility in Henan follows the Chinese national guidelines, 
which recommend that HIV-infected individuals with CD4 counts less than 200 cells/µl or 
WHO clinical stage3 or 4 disease [23] be provided CTX prophylaxis to prevent occurrence 
of opportunistic infections such as Pneumocystis jiroveci pneumonia (PCP).
Study Design and Participants
This was a retrospective study using information extracted from the Henan Provincial free 
ART program database. The comprehensive electronic database in Henan Province which 
tracked and monitored the implementation of CTX prophylaxis enables us to explore the 
effects of CTX on survival. Since the survival information in 2012 is still under verification, 
therefore we chose 2008–2010 as our study period.
HIV-infected individuals were included for analysis if they were 15 years old or above when 
enrolled in the NFATP; started ART with first-line regimens between January 1, 2008 and 
December 31, 2010 in Henan Province; and had CTX prophylaxis information recorded at 
baseline (yes or no). Those whose CTX prophylaxis information was absent were excluded 
from the analysis. All recruited patients were followed up for 12 months after starting ART. 
Patients who self-reported transmission through mother-to-child transmission (4 cases), 
homosexual behaviors (3 cases), and injection drug use (4 cases) were excluded from 
analysis due to small sample size.
Outcome Measures
The effect of CTX prophylaxis was evaluated by comparing mortality after ART initiation 
between patients on ART plus CTX prophylaxis and ART only at 3-months and 12-months. 
We also performed analysis adjusting for other demographic and medical risk factors for 
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mortality, such as gender, age at ART initiation, tuberculosis (TB) history, CD4 count at 
ART initiation and transmission route and the year of ART initiation. Year of ART 
enrollment was included in the analysis, because in 2008–2010 China raised the 
immunological criteria for ART initiation from a CD4 count of 200 cells/µl to 350 cells/µl 
[23].
Statistical Analyses
All statistical analyses were conducted using Statistical Package for the Social Sciences 
(SPSS) 16.0. Continuous variables were expressed using mean (±standard deviation) or 
median and compared using t-test; categorical variables were estimated by frequency and 
percentage and compared using Chi-square tests. Mortality was calculated by dividing the 
number of deaths by the total number of person-years (PY) of observation after ART 
initiation in the CTX group and non-CTX group for the 0–3 month interval (3-months 
mortality) and for the 0–12 month interval (12-months mortality), respectively. PY were 
calculated as time from the date of ART initiation to death or to the date of censoring. 
Patients were censored at the date of loss follow-up or the administrative censoring date (3-
months or 12-months after ART initiation), whichever occurred first. Kaplan-Meier survival 
analysis was performed to compare cumulative survival probabilities for HIV-infected 
individuals in the CTX group and non-CTX groups. A log rank test was conducted to test 
the significance of the difference. Univariate and multivariate Cox proportional hazard (PH) 
[27] models were used to examine the associations between risk factors and survival. The 
multivariable Cox PH model was generated using a forward selection approach. Variables 
were entered and kept in the model based on possible associations in previous literature and 
p-value cut-off value of 0.05 and 0.10, respectively. A p-value <0.05 was considered 
statistically significant.
Ethical Considerations
This study protocol was approved by the Institutional Review Board (IRB) of Henan 
Provincial Center for Disease Control and Prevention and the IRB of the National Center for 
AIDS Control and Prevention. The protocol was also reviewed and approved by the Office 
of the Associate Director of Science of the Center for Global Health, US CDC.
RESULTS
A total of 2,529 eligible HIV-infected individuals were identified with 2,429 person-years 
(PY) of follow-up. Of these, 2,018 received CTX prophylaxis treatment at ART initiation 
and 511 did not. By 12 months after ART, 154 patients had died, 50% of whom died within 
3 months (21 in the non-CTX group vs 56 in the CTX group). Over half the patients were 
male (54.2%; 58% were infected through plasma donation. Nearly half of the patients 
(44.2%) were aged between 35 and 54 years (Table 1). Overall, 5.6% had a history of active 
TB one year prior to ART initiation. A majority (78.9%) had a CD4 count <200 cells/µl at 
ART initiation. The CTX group had a higher percentage of patients with baseline CD4 count 
<200 cells/µl (80.8%) than the non-CTX group (71%). The median baseline CD4 count was 
91 cells/µl and 132 cells/µl for the CTX group and the non-CTX group, respectively. There 
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were no significant differences between the two groups in gender, age at ART initiation, 
proportion with TB history, and transmission route.
Overall mortality at 3-months after ART initiation was nearly doubled that at 12-months 
(12.4 per 100 PY vs 6.3 per 100 PY, p<0.01). Univariate analyses demonstrated that patients 
who were male, aged ≥55 at ART initiation, or had a history of TB prior to ART treatment 
had a higher probability of death. Patients with a baseline CD4 count < 50 cells/µl had a 
higher risk of death within one year of treatment. Transmission route was not related to 
patients’ survival. The Kaplan-Meier curve (Fig. 1) showed that patients receiving CTX had 
higher survival than those without prophylaxis, although this was not statistically significant 
(log rank =1.14, p = 0.285).
The 3-month mortality was 11.3 per 100 PY for patients on CTX at ART initiation and 16.8 
per 100 PY for those not on CTX. The 12-month mortality was lower than the 3-month 
mortality, with 6.1 per 100 PY for the CTX group compared to 7.4 per 100 PY for the non-
CTX-group. While these differences were not statistically significant before adjustment, 
after controlling for other variables, patients who took CTX at ART initiation were less 
likely to die at one year after ART treatment (AHR: 0.65, 95% CI: 0.44 – 0.95; p = 0.027) 
compared to those who did not take CTX (Table 2). This protective effect was stronger at 3 
months after ART initiation (AHR: 0.53, 95% CI: 0.32 – 0.89; p = 0.017). Other factors 
significantly associated with increased risk of death at both at 3-months and 12-months after 
ART initiation were male sex (3-month mortality AHR 1.99, 95% CI 1.20 – 3.31, p=0.008; 
12-month mortality AHR 1.56, 95% CI 1.11 – 2.20, p=0.011) and TB history in the past 
year (3-month mortality AHR 3.62, 95%CI 2.00 – 6.54, p<0.001; 12-month mortality AHR 
2.59, 95% CI 1.63 – 4.14, p<0.001). Age ≥55 years at ART initiation was associated with an 
increased mortality only at 12-months after treatment (AHR 2.21, 95%CI 1.24 – 3.95, 
p=0.007). Higher CD4 cell counts at ART initiation was an independent beneficial factor to 
patients’ survival. Patients with baseline CD4 count of 200 cells/µL or more had a nearly 
80% reduction in death both at 3-months and 12-months after ART initiation, compared 
with those with CD4 count < 50 cells/µL at baseline (3-month AHR 0.22, 95% CI 0.10 – 
0.53, p<0.001; 12-month AHR 0.21, 95% CI 0.12 – 0.39, p<0.001). The protective effect of 
baseline CD4 count of 50–199 cells/µL was weaker but was still associated with a more than 
50% decline both in 3-month and 12-month mortality compared with persons with a baseline 
CD4 count <50 cells/uL (3-month AHR 0.48 95%CI 0.29 – 0.78, p<0.001; 12-month AHR 
0.36 95%CI 0.25 – 0.52, p<0.001).
DISCUSSION
We found CTX prophylaxis provided an approximately 35% reduction in mortality in the 
first year of ART among HIV-infected individuals in central China. This result is slightly 
lower than but consistent with what has been previously reported. Currently there is limited 
information evaluating the effect of CTX prophylaxis on mortality among HIV-infected 
patients receiving ART in China. Most publications on CTX prophylaxis in the Asia-Pacific 
region are from Cambodia and Thailand [28, 29]. Our study provides additional evidence in 
the region and highlights the benefit of promoting CTX prophylaxis in conjunction with 
ART to reduce mortality among HIV patients on ART.
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Another important finding was that the protective effect of CTX was particularly strong in 
the first 3 months after ART initiation with a 47% reduction in mortality compared to those 
not on CTX. Many studies demonstrate that the first three months after ART initiation is a 
critical period. Lowrance et al. reported that a third to half of deaths occurred within three 
months of ART initiation [17]. Zhang et al. showed that mortality (22.6 per 100 PY) was 
greatest during the first three months of treatment [7]. In Zambia 71% of deaths after 
initiating ART occurred within 90 days of ART initiation, with an early mortality of 26.0 per 
100 PY [30]. Similarly, our study found exactly half of the deaths occurred in the first three 
months. This high mortality shortly after ART initiation may be mainly attributed to 
untreated AIDS rather than the immune reconstitution inflammatory syndromes [7].
In our study, we demonstrated that CTX prophylaxis decreased 3-month mortality after ART 
by nearly half. This is consistent with previously reported data. Walker et al. showed 
mortality among patients on ART with daily CTX prophylaxis was more than halved at 3 
months of treatment compared with those not on CTX [18]. The survival difference in the 
Lowrance paper was apparent as early as 40 to 45 days after ART initiation [17]. A 
substantial proportion of patients in our cohort had already progressed to advanced HIV with 
a median CD4 count <200 cells/µl at ART initiation. Even though ART was initiated, these 
patients were at a high risk for death. Their immune system was being under restoration 
during the initial ART period and was similar to those not on ART. The beneficial effect of 
CTX prophylaxis in reducing the risk of death among those patients who have only recently 
initiated ART was similar to those patients who were not on ART. Although the baseline 
median CD4 count was lower in the CTX group than that in the non-CTX group (100 
cells/µl vs130 cell/µl), the risk of death associated with lower baseline immune function was 
compensated for by CTX prophylaxis.
However, our study has three limitations that need to be considered. First, the majority of 
participants (58.5%) contracted HIV through commercial plasma donation. This is a 
manifestation of the unusual nature of the local HIV epidemic in Henan Province. 
According to the recent Chinese HIV epidemic report unprotected sexual contact is 
becoming the major transmission route of HIV infections with 46.5% by heterosexual and 
17.4% by homosexual contacts, respectively [1]. Therefore, the subjects in our study are not 
representative of the HIV-infected population in other parts of the country. It is possible that 
the survival of HIV infected people in Henan Province might be different from those who 
acquired the infection through sexual transmission since patients in this analysis who were 
infected by plasma donation in the early 1990s [24] survived without initiating ART for 
several years until 2003 when ART began to be available in China. However, in the 
multivariable analysis, we did not identify statistically significant differences in impact of 
CTX prophylaxis on 3-month or 12-month mortality among different transmission groups. 
The conclusion of our study provided strong evidence in China to support to scale up CTX 
prophylaxis together ART to reduce mortality among patients who are eligible for treatment.
Second, CTX adherence was not documented in our study. We used ART dosage as a proxy 
for overall medication adherence (Table 2), but this may not accurately reflect the adherence 
to CTX prophylaxis. Last, only information on CTX prophylaxis at ART initiation was 
collected. Initiating CTX prophylaxis at any time during ART treatment, given that the 
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criteria for CTX prophylaxis are met, may bring benefits to patients. Some patients may 
have initiated CTX prophylaxis after ART initiation and been miscategorized as not on CTX 
in our study. This could lead to an underestimation of the effect of CTX prophylaxis.
Our study demonstrated that CTX significantly reduced the mortality of HIV patients within 
the first 12 months after ART initiation in Henan Province, China with the strongest impact 
during the first 3 months. Overall uptake of OI prophylaxis and treatment among eligible 
HIV-infected individuals in China is low. In 2006, the World Health Organization (WHO) 
recommended providing CTX prophylaxis to all HIV patients with CD4 count < 350 cells/µl 
or with WHO clinical stages 2, 3 or 4 disease [31]. However, China is still using the earlier 
criteria of CD4 count ≤200 cells/µl or WHO clinical 3 or 4 disease [23]. Although our study 
did not differentiate the effect of CTX prophylaxis in person with CD4 count <350 cells/µl 
vs <200 cells/µl, we would like to recommend updating the Chinese recommendations to be 
consistent with the current WHO recommended guidelines which suggest initiating CTX 
prophylaxis at CD4 counts <350 cells/µl. This recommendation not only targets prevention 
of OIs like Pneumocystis jiroveci pneumonia (PCP) and toxoplasmosis but also enteric 
bacterial infections and isosporiasis and malaria even though there is limited information on 
these infections among HIV/AIDS patients in China.
Given the consistent results in the literature, CTX prophylaxis, in addition to ART, should 
be promoted nationwide to all eligible HIV-infected individuals-- both adults and children. 
This may help to achieve the national goal of reducing HIV-associated mortality by 30% by 
2015. More studies are needed to investigate factors that may hinder provision and uptake of 
CTX prophylaxis, as well as the optimal duration for CTX. To improve CTX prophylaxis 
monitoring, it is important to add a CTX prophylaxis component in the current web-based 
HIV case reporting system in China rather than only in the NFATP database.
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Kaplan-Meier survival curve for patients on ART* receiving CTX# compared with patients 
on ART not receiving CTX# (log rank = 1.14, df=1; p = 0.285).
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